Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists
Sponsor: GlaxoSmithKline
A PHASE2 clinical study on Advanced and / or Metastatic Liposarcoma, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 12 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
May 2020 — Aug 2020 [monthly]
Completed PHASE2
-
Aug 2018 — May 2020 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Aug 2018 [monthly]
Unknown Status PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Grupo Espanol de Investigacion en Sarcomas
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Berlin, Germany , Essen, Germany , Hanover, Germany , Madrid, Spain , Manheim, Germany , Munich, Germany , Oviedo, Spain , Palma de Mallorca, Spain , Pamplona, Spain and 5 more locations